Long-Term Oxygen Therapy

Long-Term Oxygen Therapy 7 marks High-Yield Points

Definition and purpose: LTOT is the provision of supplemental oxygen at home for at least 15 hours per day to patients with chronic severe resting hypoxaemia. Its aim is to prolong survival by reversing hypoxic pulmonary vasoconstriction and preventing cor pulmonale, not merely to relieve breathlessness.

Evidence base: Pathy's cites the Nocturnal Oxygen Therapy Trial (NOTT, Ann Intern Med 1980) — LTOT for ≥15 hours daily improved survival in severe COPD with persistent hypoxaemia, and also improved polycythaemia and neuropsychiatric function. The companion British MRC trial showed the same. Benefit is dose-dependent: the more hours per day, the greater the survival gain.

Indications (Pathy's criteria), assessed during a period of clinical stability in a current non-smoker:

Screening in practice: a simple pulse oximetry screen — refer for arterial blood gas assessment if SpO2 <93%, or <95% with possible cor pulmonale. Two arterial blood gases at least three weeks apart, taken when the patient has been stable for 8 weeks after any exacerbation, are needed before committing to LTOT.

Prerequisites and safety: the patient must have stopped smoking (fire risk and loss of benefit); optimise all medical therapy first; assess for the fire hazard of open flames, cooking and heaters. In Indian homes this includes explicit counselling about kerosene stoves, agarbatti, oil lamps and beedi smoking by family members.

Delivery systems: the oxygen concentrator is the standard home device (economical for continuous use, needs mains electricity — an important limitation where power supply is intermittent); compressed gas cylinders serve as back-up and for ambulatory use; liquid oxygen allows longer portable use but is expensive. Delivery is usually by nasal cannula at 1–4 L/min, titrated to achieve PaO2 >8 kPa (60 mmHg) or SpO2 ≥90% at rest, with the flow rate typically increased by 1 L/min during sleep and exertion.

Other forms of home oxygen (distinguish these clearly): ambulatory oxygen for exercise desaturation in patients already on LTOT or who desaturate on walking; short-burst oxygen for episodic breathlessness — Pathy's notes it "may improve symptoms of breathlessness if exercise desaturation is noted", but it has little evidence and is not a substitute for LTOT; and nocturnal oxygen for isolated sleep hypoxaemia.

Outcomes and prognosis: approximately 50% of patients receiving LTOT survive three years. Those with a low BMI and multiple comorbidities die earlier. In older adults with COPD the main predictors of mortality are disability, low BMI, lung function and the use of LTOT — that is, the need for LTOT is itself a marker of poor prognosis.

Geriatric-specific issues (a Pathy's strength — use these to score): Falls risk from extra machinery and long lengths of tubing; ask an engineer to fit switching mechanisms diverting supply to individual rooms, so tubing does not trail across the floor. Cognitive impairment and poor manual dexterity compromise safe use; this area is poorly studied. Care-home logistics — staff training and support are essential; residents using concentrators overnight may need portable cylinders with a conserver if the day room is far from the bedroom. Uncertain quality-of-life benefit: some studies found no improvement in quality of life or activities of daily living; a later study found small improvements at six months. Randomised trials have never been repeated in advanced old age, or in patients with isolated nocturnal or exertional hypoxia — an honest limitation worth stating.

Follow-up: review at 3 months, then annually — check adherence (hours used), repeat blood gases, confirm continued non-smoking, reassess the prescription, and review whether LTOT remains appropriate as the patient approaches the end of life. Latest Updates and Current Practice (2023–Present) LOTT trial (NEJM 2016) and subsequent guidance: in COPD with moderate resting desaturation (SpO2 89–93%) or isolated exercise desaturation, oxygen gave no benefit in time to death or first hospitalisation. The ATS 2020 home oxygen guideline and GOLD accordingly restrict LTOT to severe resting hypoxaemia only and make no recommendation for isolated moderate or exertional desaturation — a direct challenge to the more liberal short-burst practice described in older texts. GOLD 2026 reaffirms LTOT for severe chronic resting hypoxaemia and adds guidance on adherence-enhancing interventions for pharmacological and oxygen therapy (Eur Respir Rev 2024), recognising that prescribed hours and used hours differ widely. Current Practice Update — three points: (1) Pathy's suggests short-burst oxygen for symptomatic exercise desaturation; current guidelines do not support this, since LOTT showed no benefit outside severe resting hypoxaemia. (2) Pathy's records uncertainty about quality-of-life benefit; this is now settled — LTOT prolongs survival but does not reliably improve quality of life, and this must be explained honestly when consenting an older patient. (3) Domiciliary NIV, not oxygen alone, is now the treatment for persistent daytime hypercapnia after a COPD admission.